Chairman Lee Yun-woo boosts stake to 24.67% via open-market purchase... Limited real impact due to small volume
Chairman Lee Yun-woo (largest shareholder of DaehanPharmaceutical) purchased a total of 1,000 shares through open-market transactions on May 26 and 28, 2026 (400 and 600 shares respectively) at an average price of approximately KRW 27,230.
As a result, his total holdings increased to 1,480,404 shares, and his stake rose from 24.66% to 24.67%.
The purchase prices were slightly above the base date (May 27) closing price of KRW 27,200, indicating market-rate buying. While insider buying is often interpreted as a signal of confidence, the volume is negligible—only 0.017% of total shares outstanding—limiting any real impact on stock price or control.
Although the additional acquisition marginally strengthens the controlling shareholder's position, the scale is insufficient to provide meaningful short-term price momentum for investors.
[AI Comprehensive Analysis]The small open-market purchase slightly increased the largest shareholder's stake, but it is not a significant event for strengthening control or driving share price appreciation. No direct change to shareholder value is expected, and the status quo is likely to persist.
KOSDAQ Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders